- Home
- GKOS vs RXO Comparison
GKOS vs RXO Comparison
Compare GKOS & RXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GKOS
- RXO
- Stock Information
- Founded
- GKOS 1998
- RXO 2022
- Country
- GKOS United States
- RXO United States
- Employees
- GKOS N/A
- RXO N/A
- Industry
- GKOS Medical/Dental Instruments
- RXO
- Sector
- GKOS Health Care
- RXO
- Exchange
- GKOS Nasdaq
- RXO Nasdaq
- Market Cap
- GKOS 5.1B
- RXO N/A
- IPO Year
- GKOS 2015
- RXO N/A
- Fundamental
- Price
- GKOS $89.91
- RXO $14.47
- Analyst Decision
- GKOS Strong Buy
- RXO Hold
- Analyst Count
- GKOS 13
- RXO 17
- Target Price
- GKOS $135.15
- RXO $20.79
- AVG Volume (30 Days)
- GKOS 1.1M
- RXO 2.0M
- Earning Date
- GKOS 04-30-2025
- RXO 05-07-2025
- Dividend Yield
- GKOS N/A
- RXO N/A
- EPS Growth
- GKOS N/A
- RXO N/A
- EPS
- GKOS N/A
- RXO N/A
- Revenue
- GKOS $404,523,000.00
- RXO $5,070,000,000.00
- Revenue This Year
- GKOS $27.84
- RXO $44.04
- Revenue Next Year
- GKOS $27.88
- RXO $7.77
- P/E Ratio
- GKOS N/A
- RXO N/A
- Revenue Growth
- GKOS 23.92
- RXO 32.38
- 52 Week Low
- GKOS $77.10
- RXO $12.19
- 52 Week High
- GKOS $163.71
- RXO $32.82
- Technical
- Relative Strength Index (RSI)
- GKOS 45.80
- RXO 48.37
- Support Level
- GKOS $84.26
- RXO $12.69
- Resistance Level
- GKOS $92.27
- RXO $15.03
- Average True Range (ATR)
- GKOS 3.94
- RXO 0.82
- MACD
- GKOS 0.57
- RXO 0.29
- Stochastic Oscillator
- GKOS 58.87
- RXO 80.21
About GKOS Glaukos Corporation
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.